Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amelenodor - Landos Biopharma

Next Previous
Drug Profile

Amelenodor - Landos Biopharma

Alternative Names: ABBV-113; NX-13

Latest Information Update: 22 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Landos Biopharma
  • Class Anti-inflammatories; Benzene derivatives; Ethers; Pyridines; Small molecules
  • Mechanism of Action NLRX1 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Ulcerative colitis
  • Phase I Crohn's disease
  • Preclinical Multiple sclerosis

Most Recent Events

  • 12 Oct 2024 Pharmacodynamics data from a phase Ib trial in Ulcerative colitis presented at the 32nd United European Gastroenterology Week (UEGW-2024)
  • 27 May 2024 Phase I clinical development in Crohn's disease (In volunteers) is ongoing in Australia (PO) prior to May 2024 (Landos Biopharma pipeline, May 2024)
  • 23 May 2024 Landos Biopharma has been acquired by AbbVie

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top